A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Tolerability and Pharmacokinetics of Selumetinib After Multiple Doses in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Latest Information Update: 05 Feb 2024
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Selumetinib GI Tox
- Sponsors AstraZeneca; AstraZeneca AB
- 30 Jan 2024 Planned End Date changed from 29 Dec 2023 to 12 Jan 2026.
- 03 Aug 2023 Planned End Date changed from 31 Mar 2023 to 29 Dec 2023.
- 03 Aug 2023 Status changed from completed to active, no longer recruiting.